Observation shows complete remission of CNS ALK+ ALCL in a patient using Lorlatinib monotherapy, suggesting its potential in upfront therapy.
BACKGROUND: Pediatric Anaplastic Lymphoma Kinase-driven (ALK+) Anaplastic Large Cell Lymphoma (ALCL) offers an exciting opportunity for targeted therapy. Standard frontline chemotherapy for ALK+ ALCL is associated with severe toxicities; ALK inhibition may provide an opportunity to decrease this toxicity and improve relapse outcomes. OBSERVATION: We present a patient with both a systemic and CNS relapse of her ALK+ ALCL who achieved complete remission with ALK inhibitor monotherapy. CONCLUSION: This case supports studying the inclusion of newer ALK inhibitors in upfront therapy for pediatric ALK+ ALCL and supports the use of Lorlatinib to treat CNS relapse of ALK+ ALCL.
No takes yet. Share an insight, caveat, or question.
Vaughn et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: